Nipocalimab  (Synonyms: 尼卡利单抗; M281)

Nipocalimab (M281) is a fully humanized, recombinant, and non-glycosylated IgG1 monoclonal antibody. Nipocalimab can bind to the IgG-binding site of FcRn with high affinity and inhibit the transplacental transfer of IgG. Nipocalimab can be used in the research of fetal and neonatal hemolytic disease, myasthenia gravis, and various IgG-mediated autoimmune diseases^[1][2][3].

Human IgG1 lambda1

Human IgG1 lambda1, Isotype Control

Human

Nipocalimab (4-6 小时) 在人胎盘灌注模型中抑制了 IgG 从母体到胎儿循环的转运能力^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Nipocalimab (300 mg/kg; 每周一次; 6 个月) 在非人灵长类动物中可使 IgG 持续降低且无不良反应^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

142.12 kDa

尼卡利单抗; M281

2211985-36-1

液体

Colorless to light yellow

尼卡利单抗；尼泊卡利单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 lambda3

• 
  Immobilized Human FcRn/FCGRT&B2M Heterodimer protein, His can bind Nipocalimab. The EC₅₀ for this effect is 8.97 ng/mL.

• [1]. James S Castleman, et al. Medical therapy to attenuate fetal anaemia in severe maternal red cell alloimmunisation. Br J Haematol. 2021 Feb;192(3):425-432.  [Content Brief]

  [2]. Ling L E, et al. Selective targeting of FcRn and IgG clearance by nipocalimab preserves key immune functions. Hematology, Transfusion and Cell Therapy, 2022, 44: S13.

  [3]. Marinos C Dalakas, et al. The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. Ther Adv Neurol Disord. 2021 Feb 26;14:1756286421997381.  [Content Brief]